Skip to main content

Table 4 Expected benefit of drug combination in breast cancer therapy using entropy data from Additional file 2: Table S2 and the relationship y = −0.0005*x + 11.4732

From: Optimization of combination chemotherapy based on the calculation of network entropy for protein-protein interactions in breast cancer cell lines

  Targets Drug combination Benefit, %
BT-20   157
P00533 EGFR Gefitinib, erlotinib, cetuximab, lapatinib, panitumumab, vandetanib, trastuzumab, pertuzumab, afatinib, neratinib, AZD9291, CLO-1686a [15] 120
P62258 YWHAE Fusicoccinc [16] 91
MDA-MB-231   157
P31946 YWHAB Difopeinb [17], R18c [18] 127
P62258 YWHAE Fusicoccinc [16] 104
MDA-MB-468   229
P00533 EGFR Gefitinib, erlotinib, cetuximab, lapatinib, panitumumab, vandetanib, trastuzumab, pertuzumab, afatinib, neratinib, AZD9291, CLO-1686a [15] 146
P31946 YWHAB Difopeinb [17], R18c [18] 140
P62258 YWHAE Fusicoccinc [16] 116
MCF-7   216
P62993 GRB2 CGP78850c [19], C90b [20] 195
P06748 NPM1 NSC348884c [21] 111
T-47D   105
P62258 YWHAE Fusicoccinc [16]  
ZR-75-1   236
P62993 GRB2 CGP78850c [19], C90b [20] 162
P62258 YWHAE Fusicoccinc [16] 89
P51858 HDGF HDGF-H3b [22] 81
P06748 NPM1 NSC348884c [21] 79
BT-474   214
P31946 YWHAB Difopeinb [17], R18c [18] 151
P04626 ERBB2 Trastuzumab, pertuzumab, NeuVax vaccinea [23] 130
P62258 YWHAE Fusicoccinc [16] 127
  1. aClinical trials
  2. bPre-clinical animal models
  3. c In vitro assays